Tuesday, 26 November 2024
  
Login

Australia's most trusted
source of pharma news

Tuesday, 26 November 2024
News

Aussie GLP-1 study opens doors

Posted 26 November 2024 AM

A huge Australian-led study has demonstrated for the first time that GLP-1 receptor agonists have significant benefits for kidney disease in people both with and without diabetes, leading to calls for improved access to the drugs.

The study, published in The Lancet Diabetes & Endocrinology, found that GLP-1 RAs reduce the risk of kidney failure by 16 per cent and the worsening of kidney function by 22 per cent compared to a placebo. The combined reduction in the risk of kidney failure, worsening kidney function, and death due to kidney disease was 19 per cent.

To see the whole article, please login


Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.